カンバヤシ ケイゴ
Kanbayashi Keigo
神林 敬悟 所属 医学部 医学科(東京女子医科大学病院) 職種 助手 |
|
言語種別 | 英語 |
発表タイトル | Under-diagnosis and Under-treatment of Heterozygous Familial Hypercholesterelaemia in Patients with Cardiovascular Diseases |
会議名 | ESC CONGRESS 2017 |
主催者 | European Society of Cardiology |
学会区分 | 国際学会及び海外の学会 |
発表形式 | ポスター掲示 |
講演区分 | 一般 |
発表者・共同発表者 | SEKIGUCHI Haruki, IIDA Tatsuro, KANBAYASHI Keigo, TAKANO Mayu, ◎SAKAI Akiko, SATO Kayoko, HAGIWARA Nobuhisa |
発表年月日 | 2017/08/29 |
開催地 (都市, 国名) |
Barcelona, SPAIN |
学会抄録 | European Heart Journal 38(suppl_1),6498 2017 |
概要 | Background: Heterozygous familial hypercholesterolaemia (hFH) is most common genetic disease and cause of premature cardiovascular disease (CVD). However, the diagnosis rate is less than 0.1% in Japan.
Purpose: We examined the patients hospitalized for CVD and evaluate the extent to which hFH is underdiagnosed and undertreated. Methods: We analyzed the consecutive 553 patients hospitalized for CVD from 2013 to 2015. To investigate the prevalence of hFH, we focused on the patients with high LDL-C levels more than 140mg/dL in these CVD patients. Results: Sixty-four patients had high LDL-C levels. In those, 37 (6.7% of all CVD) patients were diagnosed as hFH (62.9±15.4 years) according to FH guidelines. We compared lipids profiles between hFH and the patients with hypercholesterolemia (DL, 68.3±15.0 years). The hFH patients had significantly higher T-cho levels (243.8±32.3mg/dL, 224.1±15.0mg/dL, P<0.01, respectively) and LDL-C levels (172.5±24.2mg/dL, 152.3±8.2mg/dL, P<0.01, respectively) than DL patients. Blood pressure, EF, TG, HDL-C, Cre, BNP, CRP were not significant difference between hFH and DL. Furthermore, 32.4% of hFH had the past history of CVD. However, just 27% of hFH were treated with statins on admission, and also only 0.05% of hFH had a definitive diagnosis at discharge. Conclusions Owing to severe underdiagnosis and under treatment of hFH, there is an urgent need for diagnostic screening together with early and aggressive treatments of high-risk condition of future cardiovascular events. |